-
Benjamin Garmezy
Oncology / HematologyBest of ASCO 2025 (GU Malignancies) - 5 day(s) agoThe 2025 ASCO Annual Meeting provided a lot of new insights and we are still trying to digest all of the new information. On Oncology…
Genitourinary Research With Ben Garmezy, MD
Oncology / HematologyDr. Garmezy joined Sarah Cannon Research Institute (SCRI) in 2021 and serves as the Associate Director of Genitourinary Research. In his role, Dr. Garmezy oversees investigational therapy trials, as well as standard of care treatments, for GU cancers, including prostate, kidney, bladder, and testicular cancers.
-
Benjamin Garmezy
Oncology / HematologyBest of ASCO 2025 - 5 day(s) ago
-
Benjamin Garmezy
Oncology / HematologyBest of ASCO 2025 - 5 day(s) ago
-
Benjamin Garmezy
Oncology / HematologyProstate T-Cell Engagers - 8 month(s) agoDear readers, At the Uromigos Live 2024 meeting, Drs. Rini, Morris, Dorff, and Autio discussed the role of T-cell engagers (TCEs) in prostate cancer. This…
-
Benjamin Garmezy
Oncology / HematologyInsights in Variant RCC Treatment - 8 month(s) agoDear readers, At The Uromigos Live 2024 meeting, Drs. Rini, Powles, Albiges, McDermott, and Hammers discussed how to approach treatment for patients with non-clear cell…
-
Benjamin Garmezy
Oncology / HematologyTROP2 ADCs in Urothelial Carcinoma: Where Do We Go From Here? - 9 month(s) agoDear readers, At the Uromigos Live & Unplugged 2024 event, Drs. Powles, Apolo, Grivas, Gupta, and Sridhar discussed the role of Sacituzumab govitecan (SG) in…
-
Benjamin Garmezy
Oncology / HematologyDear readers, At the Uromigos Live & Unplugged 2024 conference, Drs. Powles, Choueiri, Albiges, Hammers, and Zhang had a great discussion of what a definition…